Alzheimer's Disease
233,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
117 °P sammeln
  • Gebundenes Buch

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer's disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. This volume provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer's disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. This volume provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Renee D. Wegrzyn obtained her PhD in applied biology from the Georgia Institute of Technology where she studied the propagation of prion proteins in model systems. Dr. Wegrzyn was awarded an Alexander von Humboldt Research Fellowship for her postdoctoral studies to investigate de novo protein folding at the ribosome. She applied her expertise in protein folding to the challenge of developing in vitro diagnostics for neurodegenerative diseases-including Alzheimer's and prion diseases-as a group leader at Adlyfe, Inc. She is currently a scientific and technical consultant for the Department of Defense. Alan S. Rudolph is currently a member of the senior executive service and director of Biological and Chemical Technologies for the Defense Threat Reduction Agency. He was previously chief executive officer at Adlyfe Inc., an amyloid diagnostic and biomarker company, chief of Biological Sciences at the Defense Advanced Research Projects Agency, and director of Research at the Naval Research Laboratory. He has over 90 publications in diverse areas in biophysics of cryobiology and anhydrobiosis, lipid and protein self-assembly, liposome science and technology, and tissue and cellular engineering. He has a PhD in zoology from the University of California at Davis and an MBA from the George Washington University.